Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Chronic Active Antibody-Mediated Rejection Following COVID-19 Infection in a Kidney Transplant Recipient: A Case Report

Mohammad Abuzeineh, Anam Tariq, Avi Rosenberg, and Daniel C. Brennan

Johns Hopkins University School of Medicine, Division of Nephrology, Baltimore, Maryland; and Johns Hopkins University School of Medicine, Department of Pathology, Baltimore, Maryland

ABSTRACT

Kidney transplant recipients who develop coronavirus disease 2019 (COVID-19) are at increased risk of life-threatening illness, which often requires reducing immunosuppression despite the potential risk of causing an allograft rejection. Herein, we describe the clinical presentation and course of a kidney transplant recipient who acquired COVID-19 and was hospitalized with severe symptoms and hypoxemia. Upon admission, the patient was found to have elevated de novo donor-specific antibodies (DSA) yielding a positive cytotoxicity crossmatch and concurrent elevated plasma donor-derived cell-free DNA (dd-cfDNA) level, indicating a possible ongoing rejection despite improvement in his serum creatinine. Because of persistent positive COVID-19 tests and stable serum creatinine, a kidney allograft biopsy was initially deferred and his dd-cfDNA and DSA were monitored closely postdischarge. Three months later, because of persistent elevated dd-cfDNA and positive DSA, a kidney allograft biopsy was performed, which showed chronic active antibody-mediated rejection. Accordingly, the patient was treated with intravenous immunoglobulin and his maintenance immunosuppressive regimen was increased.

TREATMENT of kidney transplant recipients who acquire severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is challenging to health care professionals [1,2]. Their chronic immunosuppressed status and coexisting medical conditions put them at an increased risk of complications and higher mortality [3]. Reduction of immunosuppression, particularly discontinuation of the antimetabolite, in the setting of coronavirus disease 2019 (COVID-19) is a common practice [4,5]. Accordingly, the risk of allograft rejection, especially among high-risk transplant recipients, might be increased in the presence of ongoing infection with reduced immunosuppression and the not infrequent subtherapeutic calcineurin inhibitor levels in the presence of gastrointestinal upset and vomiting seen in COVID-19. Although histology obtained via needle biopsy remains the gold standard for the diagnosis of rejection, this technique is infrequently used for surveillance because of the cost, potential complications, and patient’s inconvenience [6]. In transplant recipients with COVID-19, a kidney allograft biopsy poses more challenges because the patients might be acutely ill, under meticulous isolation precautions, and possibly in a prone position. In addition, the risk would likely outweigh the benefits, especially in the presence of severe infection that precludes the use of “heavy” immunosuppression even in the presence of an ongoing rejection. Plasma donor-derived cell-free DNA (dd-cfDNA) detected in the blood of kidney transplant recipients has been proposed as a noninvasive marker for diagnosis of kidney allograft rejection. In this article, we present a kidney transplant recipient with COVID-19 infection who had serial elevated dd-cfDNA tests following COVID-19 illness and eventually a confirmed diagnosis of biopsy-proven chronic active antibody-mediated rejection (ABMR).

CASE PRESENTATION

A 54-year-old African American man with a medical history of end-stage kidney disease secondary to diabetes mellitus and hypertensive nephrosclerosis underwent a 3 antigen-mismatched
(HLA-1A, -1B, -1DR) deceased-donor kidney transplant in October 2018 and was maintained on triple immunosuppression with tacrolimus (target trough 4-7 ng/mL), mycophenolate 1000 mg twice daily, and prednisone 5 mg daily. His posttransplant baseline serum creatinine (SCr) was 1.4 to 1.6 mg/dL, and he had no baseline proteinuria.

Eighteen months following his kidney transplant, the patient developed a fever of 100.7°F and watery diarrhea with 5 to 6 bowel movements daily for 3 days associated with nausea and a few episodes of vomiting. He also noticed loss of taste and smell. Accordingly, he was tested for COVID-19 via nasopharyngeal swab, which was positive for SARS-CoV-2. He was initially seen virtually through a telemedicine visit, at which time his vital signs were blood pressure (BP) of 134/73 mm Hg and pulse of 86 bpm. He reported no shortness of breath, chest pain, or cough. The patient was advised to increase oral fluid intake, monitor his symptoms, and self-quarantine at home with frequent monitoring of his vital signs. His mycophenolate dose was reduced to 500 mg twice daily.

Two days following the tele-visit, he reported increased lethargy and reduced oral intake. He missed his medications, including his immunosuppressive medications, for 2 days and continued to have watery diarrhea. He was referred to the emergency department for further evaluation and possible admission. In the emergency department, his BP was 144/71 mm Hg, pulse 86 bpm, temperature 99.9°F, respiratory rate 20 breaths per minute, and oxygen saturation 93% on room air. Physical exam was remarkable for dry mucous membranes, and chest exam revealed bilateral coarse crepitations over lower lung zones. A chest x-ray showed bilateral peripheral patchy opacities, compatible with COVID-19 pneumonia. Urinalysis was remarkable for 2+ protein, and 5 red blood cells per high power field. His initial labs showed SCr of 2.6 mg/dL; blood urea nitrogen, 61 mg/dL; white blood cell count, 8.32 K/cu mm; absolute lymphocyte count, 0.69 K/cu mm; hemoglobin, 12.6 g/dL; and platelets, 231,000 K/cu mm. Serum ferritin was 4028 ng/mL; erythrocyte sedimentation rate, 89 mm/hr; C-reactive protein, 13.8 mg/dL; and interleukin-6, 64.6 pg/mL. He was started on intravenous fluids, mycophenolate was discontinued, and he was placed on oxygen at 3 L/min via nasal cannula. An ultrasound of the renal allograft showed mild hydropnephrosis.

The following day (day 2 of admission), his oxygen requirements worsened, requiring 70% FiO2 via high-flow nasal cannula. He was kept in a prone position and was started on intravenous cefepime and oral doxycycline to cover for a possible superimposed bacterial infection and he was started on isavuconazole and micafungin to empirically cover for fungal infections. Given his high inflammatory markers and increased oxygen demands, he received intravenous tocilizumab at 4 mg/kg and was started on valacyclovir for viral prophylaxis. His SCr increased to 3.4 mg/dL despite fluids. A bladder scan showed 448 mL of urine and accordingly a Foley’s catheter was inserted. Tacrolimus level was elevated at 16.6 ng/mL and the dose was adjusted. On hospital day 4, his oxygen requirements started to improve, SCr began to trend downward to 2.8 mg/dL, and C-reactive protein trended downward to 2.9 mg/dL. He continued to have clinical improvement and was weaned off oxygen and his SCr continued to improve.

Because of the history of low-level donor-specific antibodies (DSAs) to HLA-DR7 and -DR53 (well below flow cytometric crossmatch level), a test was done on day 12 of hospital admission, which showed continued presence of DSAs to HLA-DR7 and -DR53 and, of concern, new DSAs to HLA-DQA2 and DQB2 were present at a level compatible with a positive cytotoxicity crossmatch. At that time, SCr was 1.6 mg/dL, which was close to baseline, and the urine protein-to-creatinine (UPC) ratio was 0.7 g/g. On hospital day 14, another sample showed continued presence of DSAs to HLA-DR7, -DR53, -DQA2, and -DQB2 and DSAs to HLA-DQB9 and -DP20 were present. Collectively, DSAs were at a levels sufficient to yield a positive cytotoxicity crossmatch. Additionally, plasma dd-cfDNA level was tested and was elevated at 4.3%. Because of the improvement in SCr, we decided to avoid renal biopsy and continue close monitoring. On hospital day 16, the patient was discharged home because he was completely off oxygen support for multiple days and was symptom free. SCr on discharge was 1.9 mg/dL and tacrolimus levels were at goal (4-7 ng/mL). Serial follow-up dd-cfDNA levels, along with DSA, SCr, and tacrolimus levels and COVID-19 tests, are shown in Table 1. dd-cfDNA continued to be elevated; however, because of the stable SCr level and persistent positive COVID-19 tests, a renal biopsy was deferred. On day 73 following discharge, the patient complained of a 30 lb weight gain, with worsening bilateral lower limb and scrotal edema associated with elevated BP and proteinuria of 0.56 g/g on UPC. He was admitted to the hospital for intravenous diuresis. Following diuresis, his SCr rose to 2 mg/dL and a recent dd-cfDNA was elevated at 3.5%. Accordingly, he underwent a renal allograft biopsy, which showed features of chronic active ABMR (g3, l1, t0, v0, ptc3, t1l, c63, c60-1, e0-1, cX, mm3, ab0, C4d0; Fig 1). He received a total of 1 gm/kg of intravenous immunoglobulin and was restarted on mycophenolate 250 mg twice daily because his absolute lymphocyte count at that time was 1.1 K/cu mm. His edema improved with diuresis and he was discharged on oral diuretics. His most recent SCr was 1.5 g/dL and UPC was 0.8 g/g (obtained 23 months posttransplant and 5 months following initial COVID-19 presentation).

DISCUSSION

When the COVID-19 pandemic unfolded, special concerns were raised in particular with regard to solid organ transplant recipients [7]. Multiple studies showed higher disease severity and mortality among these patients [1,8]. Thus, a careful approach should be sought to achieve a balance between the risk of a severe and possibly life-threatening illness and the potential risk of “rejecting” the allograft as a result of reducing or withholding immunosuppression. In this article, we highlighted the latter.

In our patient, the presence of preexisting low-level de novo DSAs (which were absent at the time of transplant) placed him at an increased risk for developing ABMR. The severity of COVID-19 infection necessitating reduction of immunosuppression potentially triggered further new HLA DSAs, which were not present prior to his presentation, in addition to his previous HLA DSA. His initial acute kidney injury was clinically explained by reduced oral intake, diarrhea, elevated tacrolimus level, and urinary retention; rejection was less likely. However, the patient did receive tocilizumab as a part of COVID-19 directed therapy, which was followed by an improvement in SCr. Tocilizumab is proposed as a treatment modality for acute ABMR [9] and for chronic active ABMR [10,11]. When used for rejection, the dose is higher and is given monthly [10]. The improvement in SCr in our patient to a value close to baseline
Table 1. Serial Serum Creatinine, Tacrolimus Level, dd-cfDNA, and COVID-19 Tests During Hospitalization and Postdischarge

| Day 1        | Hospital Day | Postdischarge |
|--------------|--------------|---------------|
|              | Day 1        | Day 1         |
| Serum creatinine (mg/dL) | 2.6          | 1.8           |
| Tacrolimus level (ng/mL)  | 1.9          | 5.6           |
| dd-cfDNA (%)           | 2.6          | 5.1           |
| Follow-up COVID-19 tests (NP NAT) | Positive | Positive |

| Day 7          | Hospital Day | Postdischarge |
|----------------|--------------|---------------|
|              | Day 7        | Day 7         |
| Serum creatinine (mg/dL) | 1.8          | 4.1           |
| Tacrolimus level (ng/mL)  | 3.0          | 7.8           |
| dd-cfDNA (%)           | 4.3          | 8.3           |
| Follow-up COVID-19 tests (NP NAT) | Positive | Positive |

| Day 14         | Hospital Day | Postdischarge |
|----------------|--------------|---------------|
|              | Day 14       | Day 14        |
| Serum creatinine (mg/dL) | 1.8          | 5.6           |
| Tacrolimus level (ng/mL)  | 3.0          | 5.1           |
| dd-cfDNA (%)           | 4.3          | 7.8           |
| Follow-up COVID-19 tests (NP NAT) | Positive | Positive |

| Day 35         | Hospital Day | Postdischarge |
|----------------|--------------|---------------|
|              | Day 35       | Day 35        |
| Serum creatinine (mg/dL) | 1.8          | 5.6           |
| Tacrolimus level (ng/mL)  | 3.0          | 5.1           |
| dd-cfDNA (%)           | 4.3          | 7.8           |
| Follow-up COVID-19 tests (NP NAT) | Positive | Positive |

| Day 56         | Hospital Day | Postdischarge |
|----------------|--------------|---------------|
|              | Day 56       | Day 56        |
| Serum creatinine (mg/dL) | 1.8          | 5.6           |
| Tacrolimus level (ng/mL)  | 3.0          | 5.1           |
| dd-cfDNA (%)           | 4.3          | 7.8           |
| Follow-up COVID-19 tests (NP NAT) | Positive | Positive |

| Day 70         | Hospital Day | Postdischarge |
|----------------|--------------|---------------|
|              | Day 70       | Day 70        |
| Serum creatinine (mg/dL) | 1.8          | 5.6           |
| Tacrolimus level (ng/mL)  | 3.0          | 5.1           |
| dd-cfDNA (%)           | 4.3          | 7.8           |
| Follow-up COVID-19 tests (NP NAT) | Positive | Positive |

| Day 77         | Hospital Day | Postdischarge |
|----------------|--------------|---------------|
|              | Day 77 (Biopsy Admission) | Day 77 |
| Serum creatinine (mg/dL) | 2.0          | 8.5           |
| Tacrolimus level (ng/mL)  | 17           | 9.2           |
| dd-cfDNA (%)           | —            | —             |
| Follow-up COVID-19 tests (NP NAT) | Negative on postdischarge | — |

COVID-19, coronavirus disease; dd-cfDNA, donor-derived cell-free DNA; NP NAT, nasopharyngeal swab nucleic acid amplification test.

Baseline (1 year prior to presentation): Very low-level DSAs to HLA-DR7 and -DR53. These DSAs were well below a level sufficient to yield a positive flow cytometric crossmatch.

Hospital day 12: Continued presence of DSAs to HLA-DR7 and -DR53. Of concern, DSAs to HLA-DQA2/DQB2 were present at a level compatible with a positive cytotoxicity crossmatch.

Hospital day 14: continued presence of DSA to HLA-DR7, -DR53, -DQA2/DQB2. Of concern, DSAs to HLA-DQA2/DQB9 and -DP20 were present at a level compatible with a positive cytotoxicity crossmatch.

Postdischarge day 70: Continued presence of DSAs to HLA-DR53, -DQA2/DQB9, and -DQA2/DQB2. DSAs to HLA-DR7 and -DP20 had decreased and were below a level considered positive. Collectively, the DSAs were at a level sufficient to yield a positive cytotoxicity crossmatch.

*Note HLA donor-specific antibodies as follows (transplant candidates and their deceased donors were typed for HLA-A, -B, -C, -DR, -DQ, and -DP by reverse sequence-specific oligonucleotide assay (One Lambda LABType), as described by Lucas et al [17]).

The greatest challenge resides in managing allograft rejection in kidney transplant recipients with a recent COVID-19 infection, especially in the presence of prolonged viral shedding, which exceeded 90 days in our patient. It remains unclear whether COVID-19 reinfection can occur, but a recent report showed a rapid decay of SARS-CoV-2 antibodies in patients with mild disease [16]. The changes in these antibodies are not yet described in transplant recipients. Therefore, we decided to treat the patient with high-dose intravenous immunoglobulin and restarted low-dose mycophenolate with a plan to increase as tolerated.

The main limitation to our study is the absence of an initial kidney allograft biopsy limiting the conclusion regarding whether the presence of chronic ABMR was a sequel of an acute ABMR following COVID-19 illness or was an ongoing diagnosis prior to COVID-19 infection that was missed because of kidney function stability and lacking an indication to screen for a rejection. The worsening of preexisting DSAs and development of new de novo DSAs during COVID-19 infection make the latter less likely. Nevertheless, the possibility of allograft rejection, whether acute or chronic, should always be considered in high-risk patients with COVID-19 infection whose immunosuppression was reduced in the setting of their acute illness. Using dd-cfDNA is an appealing option for surveillance in such patients. Performing a timely kidney allograft biopsy remains challenging in the COVID-19 era but ideally should not be delayed. Optimal timing for resumption of routine maintenance immunosuppressive regimen, including antimetabolite, following COVID-19 is unclear. However, a resumption sooner rather than later should be strongly considered in patients who are at higher risk of rejection.
REFERENCES

[1] Michaels MG, La Hoz RM, Danziger-Isakov L, et al. Coronavirus disease 2019: implications of emerging infections for transplantation. Am J Transplant 2020;20:1768–72. https://doi.org/10.1111/ajt.15832.

[2] Abuzeineh M, Muzaale AD, Crews DC, et al. Telemedicine in the care of kidney transplant recipients with COVID-19: case reports [e-pub ahead of print]. Transplant Proc https://doi.org/10.1016/j.transproceed.2020.07.009, accessed September 11, 2020.

[3] Akalin E, Azzi Y, Bartash R, et al. Covid-19 and kidney transplantation. N Engl J Med 2020;382:2475–e7. https://doi.org/10.1056/NEJMc2011117.

[4] Pereira MR, Mohan S, Cohen DJ, et al. COVID-19 in solid organ transplant recipients: initial report from the US epicenter. Am J Transplant 2020;20:1800–e8. https://doi.org/10.1111/ajt.15941.

[5] Yi SG, Rogers AW, Saharia A, et al. Early experience with COVID-19 and solid organ transplantation at a US high-volume transplant center [e-pub ahead of print]. Transplantation https://doi.org/10.1097/TP.0000000000003339, accessed September 11, 2020.

[6] Morgan TA, Chandran S, Burger IM, Zhang CA, Goldstein RB. Complications of ultrasound-guided renal transplant biopsies. Am J Transplant 2016;16:1298–305. https://doi.org/10.1111/ajt.13622.

[7] Boyarsky BJ, Po-Yu Chiang T, Werbel WA, et al. Early impact of COVID-19 on transplant center practices and policies in the United States [e-pub ahead of print]. Am J Transplant https://doi.org/10.1111/ajt.15915, accessed September 11, 2020.

[8] Kates OS, Haydel BM, Florman SS, et al. COVID-19 in solid organ transplant: a multi-center cohort study [e-pub ahead of print]. Clin Infect Dis https://doi.org/10.1093/cid/ciaa1097, accessed September 11, 2020.

[9] Pottebaum AA, Venkatachalam K, Liu C, et al. Efficacy and safety of tocilizumab in the treatment of acute antibody-mediated rejection in kidney transplant recipients. Transplant Direct 2020;6:e543. https://doi.org/10.1097/TP.0000000000000988.

[10] Choi J, Aubert O, Vo A, et al. Assessment of tocilizumab (anti-interleukin-6 receptor monoclonal) as a potential treatment for chronic antibody-mediated rejection and transplant glomerulopathy in HLA-sensitized renal allograft recipients. Am J Transplant 2017;17:2381–9. https://doi.org/10.1111/ajt.14228.

[11] Shin B-H, Every MJ, Zhang H, et al. Impact of tocilizumab (anti-HLA) treatment on immunoglobulins and anti-HLA antibodies in kidney transplant patients with chronic antibody-mediated rejection. Transplantation 2020;104:856–63. https://doi.org/10.1097/TP.0000000000002895.

[12] Garg N, Hidalgo LG, Aziz F, et al. Use of donor-derived cell-free DNA for assessment of allograft injury in kidney transplant recipients during the time of the COVID-19 pandemic [e-pub ahead of print]. Transplant Proc https://doi.org/10.1016/j.transproceed.2020.07.013, accessed September 11, 2020.

[13] Bloom RD, Bromberg JS, Poggio ED, et al. Cell-free DNA and active rejection in kidney allografts. J Am Soc Nephrol 2017;28:2221–22. https://doi.org/10.1681/ASN.2016091034.

[14] Oellerich M, Shipkova M, Asendorf T, et al. Absolute quantification of donor-derived cell-free DNA as a marker of rejection and graft injury in kidney transplantation: results from a prospective observational study. Am J Transplant 2019;19:3087–99. https://doi.org/10.1111/ajt.15416.
[15] Dholakia S, De Vlaminck I, Khush KK. Adding insult on injury: immunogenic role for donor-derived cell-free DNA? [e-pub ahead of print]. Transplantation https://doi.org/10.1097/TP.000000000003240, accessed September 11, 2020.

[16] Rapid decay of Anti-SARS-CoV-2 antibodies in persons with mild COVID-19 [e-pub ahead of print]. N Engl J Med https://doi.org/10.1056/NEJMx200017, accessed September 11, 2020.

[17] Lucas DP, Leffell MS, Zachary AA. Differences in immunogenicity of HLA antigens and the impact of cross-reactivity on the humoral response. Transplantation 2015;99:77–85. https://doi.org/10.1097/TP.000000000000355.